drugset / Trial / NCT00390871

Acute Neurological ICU Sedation Trial (ANIST)

NCT00390871

Phase 2 Completed 35 enrolled Johns Hopkins University
RandomizedCrossoverQuadruple-blindTreatment

Summary

Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.

Timeline

Start
2005-05
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified Intravenous
Comparator Propofol Small molecule
Comparator Fentanyl Other / unclassified

Indications

No indication recorded.